Boston Immune Technologies and Therapeutics, Inc.
Publicly observedWinchester, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Winchester | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Boston Immune Technologies and Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MWNARWHZWRM5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant21 Aug 2023Publicly observed
NIH SBIR/STTR award: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
USD 990,243.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 Aug 2023Publicly observed
NIH SBIR/STTR award: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
USD 926,858.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2021Publicly observed
NIH SBIR/STTR award: Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
USD 2,409,283.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.